SGT-501

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Catecholaminergic Polymorphic Ventricular Tachycardia

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Trial Timeline

Feb 23, 2026 → May 1, 2031

NCT ID

NCT07148089

About SGT-501

SGT-501 is a phase 1 stage product being developed by Solid Biosciences for Catecholaminergic Polymorphic Ventricular Tachycardia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07148089. Target conditions include Catecholaminergic Polymorphic Ventricular Tachycardia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07148089	Phase 1	Recruiting	Feb 23, 2026	May 1, 2031	Catecholaminergic Polymorphic Ventricular Tachycardia

Other Products from Solid Biosciences

SGT-003 + PlaceboPhase 3

SGT-212Phase 1